""iCAD is committed to delivering revolutionary technology that supports healthcare professionals in providing quality care to patients worldwide,"" said Ken Ferry, CEO, iCAD. ""With the addition of PowerLook Tomo Detection and Xoft IORT, our providers are armed with proven technological advancements that offer our patients valuable, life-changing benefits."" Saunders, FACHE, President and CEO, Navicent Health. ""Our adoption of iCAD's premier products for the detection and treatment of breast cancer underscores our commitment to elevating health and well-being through compassionate, personalized care,"" said Dr. The new offerings also coincide with the hospital's ""Paint the Town Pink"" community campaign for National Breast Cancer Awareness Month in October.
The comprehensive technologies are available at Navicent Health's Peyton Anderson Cancer Center and mark an important advancement for the more than 8,000 women who will be diagnosed with breast cancer this year in Georgia. The hospital is also the first in the state to offer IORT with the Xoft System. Navicent Health, based in Macon, Ga., is now the first health system in the country to offer iCAD's most advanced solutions for both the detection and treatment of breast cancer. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that its complete suite of leading-edge breast health innovations including PowerLook® Tomo Detection, a radiology workflow solution built on artificial intelligence, and the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® for the treatment of early-stage breast cancer using intraoperative radiation therapy (IORT), are now available at The Medical Center, Navicent Health, the second largest hospital in Georgia. NASHUA, N.H., and MACON, Ga., (Tuesday, October 30, 2018) - iCAD, Inc. Prominent medical center is first in the United States to expand breast health offerings with iCAD's PowerLook Tomo Detection solution and Xoft System Sassine earned a Bachelor of Arts degree at the University of Iowa in 1987 and an MBA from the Wharton School at the University of Pennsylvania in 1993.Navicent Health Adopts iCADs Breast Cancer Detection and Therapy Solutions to Enhance Patient Care Tippie College of Business, University of Iowa Board of Advisors from 2009 to 2018. Sassine has been a member of the Henry B. Sassine joined Fidelity as a high yield research analyst, covering the Telecommunications, Satellite, Technology, Defense and Aerospace, and Restaurant Industries and in 2001, joined the international group as a research analyst covering small and mid-cap international stocks. Between 20, he managed the Fidelity Small Cap Stock Fund, the Fidelity International Small Cap Opportunities Fund and the Fidelity Advisor International Small Cap Opportunities Fund.
Sassine served in various positions at Fidelity Investments from 1999 to 2012, including, most recently as Portfolio Manager. is a leading provider of advanced image analysis, workflow solutions and radiation therapy for early detection and treatment of cancer. He also serves on the Board of Directors of Nasdaq listed ICAD Inc. Andy Sassine is currently, and has been since January 2019, the Chief Financial Officer at Arcturus Therapeutics.
0 kommentar(er)
